- Lobbying
- Grant AND Couch
Lobbying Arrangements Results for 'Grant Couch'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials. |
Avanir Pharmaceuticals, Inc.
|
VENN STRATEGIES | |||
Details - General Issues related to research, innovation, and extension. - Farm Bill Reauthorization: General issues related to nutrition, research, and extension. -H.R. 4368/S. 2131, the Agriculture Appro... |
The Ohio State University
|
in-house lobbying | |||
Details Policies related to biopharmaceutical access and innovation. |
UCB, Inc.
|
VENN STRATEGIES | |||
Details Issues related to home and community-based healthcare services legislation under development in the House and Senate, specifically H.R.4131 and S.2210, the Better Care Better Jobs Act. |
Premier Home Health Care Services, Inc.
|
VENN STRATEGIES | |||
Details Issues related to ensuring patient access to medications under the Medicare Part D program, specifically those in the six protected classes. |
Partnership for Part D Access
|
VENN STRATEGIES | |||
Details Discussions regarding the Department of Veterans Affairs proposed rule (RIN 2900-AP89 Change in Rates VA Pays for Special Modes of Transportation) and related legislation: VA Emergency Transportati... |
Global Medical Response, Inc.
|
in-house lobbying | |||
Details Value-based physician reimbursement; regulatory improvements in value-based payment models; improving the Medicare Advantage program; access to administrative claims data; chronic care management; ... |
American Medical Group Association
|
in-house lobbying | |||
Details Issues relating to increasing patient and provider access to non-opioid approaches for acute pain management. |
Voices for Non-Opioid Choices
|
VENN STRATEGIES | |||
Details General issues related to the bio-pharmaceutical sector, innovation, patient access, health care manufacturing, and pandemic preparedness/response. Measures related to U.S. international and corpor... |
Regeneron Pharmaceuticals, Inc.
|
VENN STRATEGIES | |||
Details Legislation and other proposed policy change impacting S Corporation ESOPs. |
EMPLOYEE-OWNED S CORPORATIONS OF AMERICA
|
VENN STRATEGIES | |||
Details Medicare sequester, PAYGO H.R. 2474, Strengthening Medicare for Patients and Providers Act: an annual inflation adjustment to Medicare physician payments S. 1512, CONNECT for Health Act of 2021: T... |
American Society of Anesthesiologists
|
in-house lobbying | |||
Details Supporting the following funding levels in FY24 appropriations bills: LHHS- $500 million for the Agency for Healthcare Research and Quality, $11.6 billion for the Centers for Disease Control and Pr... |
NATIONAL MULTIPLE SCLEROSIS SOCIETY
|
in-house lobbying |